Jiva Pharma
JIVA Pharma, Inc. is revolutionizing the pharmaceutical and neutraceutical industries through world-class science, innovation, and platform technologies. Their patented portfolio of products aims to create a healthier world, operating through two key divisions: Pharmaceuticals and Neutraceuticals & Cosmeceuticals. The company is founded by Dr. Om P. Goel, PhD, an experienced scientist with numerous patents and a history of developing significant drugs and products for consumer health.
Industries
Nr. of Employees
small (1-50)
Jiva Pharma
P.O. Box # 1202, 2075 West Stadium Blvd., Ann Arbor, MI 48106
Patents
5-substituted 2,4-thiazolidinediones (thiohydantoins), pseudothiohydantoins, and propseudothiohydantoins for use as antiviral agents
US-11202774-B2
View Details5-substituted 2,4-thiazolidinediones (thiohydantoins), pseudothiohydantoins, and propseudothiohydantoins for use as antiviral agents
US-10646477-B1
View DetailsFormulations of concentrated prunes and prebiotics as laxatives and dietary supplements
US-9808497-B2
View DetailsThiazolidinediones of omega-3 polyunsaturated acids as new insulin sensitizers for treating type2 diabetes
US-9364465-B2
View Details
5-substituted 2,4-thiazolidinediones (thiohydantoins), pseudothiohydantoins, and propseudothiohydantoins for use as antiviral agents
US-11202774-B2
View Details5-substituted 2,4-thiazolidinediones (thiohydantoins), pseudothiohydantoins, and propseudothiohydantoins for use as antiviral agents
US-10646477-B1
View DetailsFormulations of concentrated prunes and prebiotics as laxatives and dietary supplements
US-9808497-B2
View DetailsThiazolidinediones of omega-3 polyunsaturated acids as new insulin sensitizers for treating type2 diabetes
US-9364465-B2
View DetailsProducts
JP-1 (JIVA-001)
Patented small-molecule development candidate intended for treatment of early-stage Alzheimer’s disease; development supported by an issued U.S. patent.
JP-0054 (antiviral topical candidate)
Lead small-molecule antiviral candidate developed for topical treatment of herpes simplex (HSV-1, HSV-2) and varicella-zoster virus; demonstrated in vitro cellular activity and in vivo efficacy in mice models with prototype formulation work and GLP batch planning.
Prune/prebiotic nutritional supplement (commercial product)
A consumer-facing nutritional product formulated for colon health and relief of constipation; developed and marketed with an issued U.S. patent.
JP-1 (JIVA-001)
Patented small-molecule development candidate intended for treatment of early-stage Alzheimer’s disease; development supported by an issued U.S. patent.
JP-0054 (antiviral topical candidate)
Lead small-molecule antiviral candidate developed for topical treatment of herpes simplex (HSV-1, HSV-2) and varicella-zoster virus; demonstrated in vitro cellular activity and in vivo efficacy in mice models with prototype formulation work and GLP batch planning.
Prune/prebiotic nutritional supplement (commercial product)
A consumer-facing nutritional product formulated for colon health and relief of constipation; developed and marketed with an issued U.S. patent.
Expertise Areas
- Small-molecule drug discovery
- Preclinical development and animal models
- Topical antiviral therapeutics
- Nutraceutical formulation and commercialization
Key Technologies
- Small-molecule medicinal chemistry
- In vitro antiviral cell-based assays
- In vivo efficacy models (mice, guinea pig)
- Topical formulation development
News & Updates
JIVA Pharma was recognized as a 2013 Michigan Excellence Award recipient by the U.S. Trade & Commerce Institute (USTCI).
JIVA Pharma was recognized as a 2013 Michigan Excellence Award recipient by the U.S. Trade & Commerce Institute (USTCI).